A new discovery suggests targeting opioid receptor pathway could create pain medications without the risk of addiction or hallucinations
Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive.
For decades, scientists have attempted to develop drugs that selectively activate one type of opioid receptor to treat pain while not activating another type of opioid receptor linked to addiction. Unfortunately, those compounds can cause a different unwanted effect; hallucinations.
But a new study led by Washington University School of Medicine in St. Louis has identified a potential route to pain relief that neither triggers addiction nor activates the pathway that causes hallucinations.
Painkilling drugs such as morphine and oxycodone, as well as illegal street drugs such as heroin and fentanyl, activate what are known as mu opioid receptors on nerve cells.
Those receptors relieve pain but also cause euphoria – the feeling of being high – and that feeling contributes to addiction.
An alternative strategy is to target another opioid receptor, called the kappa opioid receptor. Scientists attempting to make drugs that target only the kappa receptor have found that they also effectively relieve pain, but they can be associated with other side effects such as hallucinations.
Researchers at the Center for Clinical Pharmacology at Washington University School of Medicine and the University of Health Sciences & Pharmacy, also in St Louis, have identified the potential mechanisms behind such hallucinations, with the goal of developing painkillers without this side effect.
Using electron microscopes, they identified the way that a natural compound related to the salvia plant selectively binds only to the kappa receptor but then causes hallucinations.
Principal investigator Tao Che, PhD, an assistant professor of anaesthesiology, said: “Since 2002, scientists have been trying to learn how this small molecule causes hallucinations through kappa receptors.
“We determined how it binds to the receptor and activates potential hallucinogenic pathways, but we also found that other binding sites on the kappa receptor don’t lead to hallucinations.”
- Receptor location matters for psychedelic drug effects
- New guidelines on nitrous oxide abuse and spinal cord damage
- AI tool able to detect patients’ injected drug use
Safer pain-relieving drugs
Developing new drugs to target these other kappa receptor binding sites may relieve pain without either the addictive problems associated with older opioids, or the hallucinations associated with the existing drugs that selectively target the kappa opioid receptor.
Targeting the kappa receptor to block pain without hallucinations would be an important step forward, according to Che, because opioid drugs that interact with the mu opioid receptor have led to the current opioid epidemic, causing more than 100,000 overdose deaths in the US in 2021.
Che said: “Opioids, especially synthetic opioids such as fentanyl, have contributed to far too many overdose deaths. There’s no doubt we need safer pain-relieving drugs.”
Che’s team, led by first author Jianming Han, PhD, a postdoctoral research associate in Che’s laboratory, found that a class of signalling proteins called G proteins cause the kappa opioid receptor to activate several different pathways.
Han said: “There are seven G proteins linked to the kappa receptor, and although they are very similar to each other, the differences between the proteins may help explain why some compounds can cause side effects such as hallucinations.
“By learning how each of the proteins binds to the kappa receptor, we expect to find ways to activate that receptor without causing hallucinations.”
The function of the G proteins has largely been unclear until now, particularly the protein that activates the pathway linked to hallucinations.
Che added: “All of these proteins are similar to one another, but the specific protein subtypes that bind to the kappa receptor determine which pathways will be activated.
“We have found that the hallucinogenic drugs can preferentially activate one specific G protein but not other, related G proteins, suggesting that beneficial effects such as pain relief can be separated from side effects such as hallucinations.
“So, we expect it will be possible to find therapeutics that activate the kappa receptor to kill pain without also activating the specific pathway that causes hallucinations.”
The research is published in Nature.
Image: Scientists at the Center for Clinical Pharmacology at Washington University School of Medicine and the University of Health Sciences & Pharmacy have identified a potential pathway to pain relief that neither triggers addiction nor causes hallucinations. Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive. © Che Lab Washington University.
